Video Shorts

Real-World Experience With BCG Retreatment After BCG Failure in NMIBC

Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Prostate Cancer

Examining the Landscape of Biomarkers in RCC

Sequencing T-Cell–Redirecting Therapies in Multiple Myeloma

Breaking Down the FDA Approval of Nivolumab AVD for Untreated Classical Hodgkin Lymphoma

Unpacking the Design of the NCCN Advocacy Academy

Pan-RAS Inhibition Opens New Therapeutic Frontiers in Pancreatic Cancer

Outlining the Importance of Updated WHO Diagnostic Criteria for AML

Understanding Why the FDA Approval of Sonrotoclax for MCL is Important

AI-Powered Imaging May Change Early Pancreatic Cancer Detection

Expert Insights on FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

The Implications of the SATEEN Trial in HER2+ Metastatic Breast Cancer

Tracking the Evolution of Radiopharmaceuticals in Prostate Cancer

Managing Mogamulizumab-Associated Rash in CTCL

Highlighting the Advantages of Proton Therapy

Contextualizing the VIKTORIA-1 Trial in Breast Cancer Prior to ASCO 2026

Treatment and Clinical Trial Considerations in Myeloma Subgroups

OncLive News Roundup for the Week of 5/3

Highlighting the Importance of Raising Bladder Cancer Awareness

Evolving Management of p53-Mutated Mantle Cell Lymphoma

MANEUVER Trial Supports Integration of Targeted Therapy Into Upfront TGCT Management

Discussing the Implications of the SERENA-6 Trial Design

Addressing Challenges With Anemia Management in Myelofibrosis

Breaking Down the Current State of CAR T-Cell Therapies in PCNSL

MountainTAP-30 Trial Seeks to Leverage PRMT5 Inhibitor for MTAP-Deleted Pancreatic Cancer

Frontline Treatment and Transplant Considerations in Multiple Myeloma

The Pathologist's Role in Breast Cancer Biomarker Testing

Early RAS Inhibitor Data Signal Rare Momentum in Metastatic Pancreatic Cancer

Spotlighting the Nuances of the SERENA-6 Trial Design Following the FDA's ODAC Vote

Highlighting the Importance of Mentorship for Early-Career Cancer Researchers